RE: Colin bird14 Apr 2026 12:39
No one is saying that the recently added Molefe isn't good. It's a shame with the potential Bird couldn't even be bothered to promote the very good Rns from Jlp by at least putting the same news out.
Shareholders are right to ask what is going on with our existing assets, particularly Luansobe, for which far too little is perceived to be being done.
And as much as the usuals bang the drum, the share price remains ridiculously moribund and trades show that very few have any desire to own it. You can argue as much as you like but the share price is a marker of success and at the end of the day Bird continues to fail in increasing shareholder value.